Protective effect of nafamostat mesilate on injury of porcine hepatocytes by human plasma.
Nafamostat mesilate (NM), a protease inhibitor, possesses a cytoprotective effect and inhibits the activation of complement. The present study investigated whether NM has any protective effect against injury of porcine hepatocytes by human plasma in a bioartificial liver support system. Porcine hepatocytes were harvested and seeded at a density of 2 x 10(5) cells on a 35-mm collagen-coated plate in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum. Twenty-four hours later, the medium was replaced with human plasma with three concentrations of NM between 3.8 x 10(-5) and 3.8 x 10(-4) M and then cultured for 6 h. The viability of porcine hepatocytes, lactate dehydrogenase (LDH) levels, lidocaine clearance, porcine albumin production, and changes in complement (C3) levels were measured. The viability of porcine hepatocytes in human plasma decreased significantly to 37.7 +/- 11.4% of that in DMEM. NM improved the viability of the hepatocytes, lowered the levels of LDH, and increased lidocaine clearance and albumin production in a concentration-dependent manner. The concentrations of C3, the marker of xenogeneic reactions, did not change significantly, indicating that no hyperacute xenogeneic reaction occurred in our series. Together, our results suggested that NM exerts favorable effects on porcine hepatocytes in human plasma through direct effect such as prevention of protease activity in the plasma membrane of porcine hepatocytes rather than inhibition of complement-dependent immunoreactions.
Kawazoe
Y
Y
Department of Surgery II, Nagasaki University School of Medicine, Sakamoto, Japan.
Eguchi
S
S
Sugiyama
N
N
Yuzawa
H
H
Kawashita
Y
Y
Fujioka
H
H
Kanematsu
T
T
D000418:Albumins / Q000096:biosynthesis; D000779:Anesthetics, Local / Q000493:pharmacokinetics; D000818:Animals; D001550:Benzamidines; D001798:Blood Proteins / Q000009:adverse effects*; D002470:Cell Survival / Q000187:drug effects; D017690:Cell Transplantation; D002478:Cells, Cultured; D003176:Complement C3 / Q000032:analysis / Q000494:pharmacology; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D008012:Lidocaine / Q000493:pharmacokinetics; D008099:Liver / Q000166:cytology* / Q000201:enzymology; D019164:Liver, Artificial; D011480:Protease Inhibitors / Q000494:pharmacology*; D013552:Swine; D014183:Transplantation, Heterologous
D000418:Albumins; D000779:Anesthetics, Local; D001550:Benzamidines; D001798:Blood Proteins; D003176:Complement C3; D006146:Guanidines; D011480:Protease Inhibitors; D008012:Lidocaine; D007770:L-Lactate Dehydrogenase; C032855:nafamostat